Zacks Investment Research · Mar 15, 2023
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
NASDAQ · BLCM
Bellicum Pharmaceuticals, Inc.
Healthcare · Biotechnology
$0.07
Down-$0.01 (-6.62%)
Updated Aug 15, 2026, 10:32 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 778.33K
- P/E ratio
- -0.09
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 6.06K
- Avg. volume
- 27.95K
Price performance
BLCM price history
1M range · 0 trading sessions · Daily adjusted prices
BLCM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BLCM news
The latest Smart Investors Daily articles mentioning BLCM.
Stock researchCompany · Overview
BLCM research
Overview
Company profile and research snapshot.
Company profile
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 16, 2022 | Ladenburg Thalmann | Buy | — |
| Oct 30, 2020 | Wells Fargo | Equal-Weight | — |
| Mar 13, 2020 | Raymond James | Outperform | — |
| Aug 9, 2018 | Citigroup | Buy | — |
| Apr 12, 2018 | Wells Fargo | Outperform | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Mar 14, 2023
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid.
Zacks Investment Research · Feb 27, 2023
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
GlobeNewswire Inc. · Jan 31, 2023
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows:
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
